Long‐term outcome of tacrolimus‐based immunosuppressive treatment for patients with paediatric‐onset lupus nephritis
Nephrology · 2024
DOI: 10.1111/nep.14406 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology, 2024. Verfasst von Hiroshi Tanaka und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nursing, Faculty of Health and Medical Care, Hachinohe Gakuin University, Hachinohe, Japan. Hauptthemen laut MEDLINE: Lupus Nephritis, Immunosuppressive Agents, Tacrolimus, Glomerular Filtration Rate. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
We have previously reported the mid‐term efficacy and safety of tacrolimus (Tac)‐based immunosuppressive therapy in such patients, and herein, we aimed to determine their long‐term outcomes (over 10 years).
Methods
We retrospectively evaluate the data of 13 consecutive patients with biopsy‐proven long‐standing LN who underwent a long‐term Tac‐based treatment regimen. Tac was administered once daily at a dose of 3 mg as reinduction or maintenance treatment. Treatment outcomes were defined using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), urinary protein/creatinine ratio (Up/cr), serum creatinine, estimated glomerular filtration rate (eGFR) and serological lupus markers (complement C3, complement hemolytic activity [CH 50], and anti‐dsDNA antibody titre), and the concomitantly administered prednisolone (PDN) dose. Data on clinical parameters and serological lupus activity were collected annually from each patient throughout the study period.
Results
The patients' baseline characteristics at the treatment initiation were as follows: mean age, 18 years; Up/cr, 0.63 ± 0.69; serum C3 level, 57.2 ± 22.4 mg/dL (normal range, 79–152 mg/dL); CH50, 27.9 ± 15.7 U/mL (normal range, 23.0–46.0 U/mL); serum anti‐dsDNA antibody titre, 111.7 ± 123.4 IU/mL (normal range,
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nursing, Faculty of Health and Medical Care, Hachinohe Gakuin University, Hachinohe, Japan.
- Department of School Health Science, Hirosaki University Faculty of Education, Hirosaki, Japan.
- Department of Pediatrics, Hirosaki University Hospital, Hirosaki, Japan.
- Niji-iro Children's Clinic, Hirosaki, Japan.
ORCID-Profile: Hiroshi Tanaka, Tomomi Aizawa
Zitieren
APA
Tanaka, H., Aizawa, T., & Endo, M. (2024). Long‐term outcome of tacrolimus‐based immunosuppressive treatment for patients with paediatric‐onset lupus nephritis. Nephrology. https://doi.org/10.1111/nep.14406
Vancouver
Tanaka H, Aizawa T, Endo M. Long‐term outcome of tacrolimus‐based immunosuppressive treatment for patients with paediatric‐onset lupus nephritis. Nephrology. 2024. doi:10.1111/nep.14406
BibTeX
@article{Tanaka2024,
author = {Tanaka, Hiroshi and Aizawa, Tomomi and Endo, Morito},
title = {Long‐term outcome of tacrolimus‐based immunosuppressive treatment for patients with paediatric‐onset lupus nephritis},
journal = {Nephrology},
year = {2024},
doi = {10.1111/nep.14406}
}
EUVIMED